Advertisement

Topics

Evaluate: Median Cost Per Patient for Orphan Drugs is 5.5 Times Higher Than Non-Orphan Drugs

23:00 EST 27 Feb 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Annual “EvaluatePharma® Orphan Drug 2017 Report” sees continued growth (CAGR 2017 to 2022:+11.1%)for orphan drugs, approximately double overall prescription market growth The steady and inexorable growth of the orphan d...

Other Sources for this Article

Evaluate and EP Vantage (for general questions)
Christine Lindgren
+1 617-866-3906
christine.lindgren@evaluategroup.com
or
Jani Communications (for U.S. media)
Janice Foley
+1-617-823-5555
janifoley@verizon.net
or
Instinctif Partners (for non-U.S. media)
Gemma Harris/Melanie Toyne Sewell
+44 (0) 20 7457 2020
evaluate@instinctif.com

NEXT ARTICLE

More From BioPortfolio on "Evaluate: Median Cost Per Patient for Orphan Drugs is 5.5 Times Higher Than Non-Orphan Drugs"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...